Endocrine
Ancient Egypt — Depictions of proportionate small stature in dynastic art, circa 2000 BCE
Growth hormone deficiency occupied medical imagination for centuries under the guise of pituitary dwarfism and disorders of bodily proportion, long before the pituitary gland was understood to regulate growth through chemical secretion. Ancient and medieval physicians attributed unusually small stature to a variety of constitutional, humoral, and supernatural causes, with no conception of a specific glandular insufficiency. The isolation and eventual synthesis of growth hormone in the twentieth century represented the culmination of a long scientific struggle that passed through anatomy, physiology, and biochemistry.
Historical Narrative
Records of individuals with markedly small stature and the proportionate features associated with what later medicine would call pituitary dwarfism reached back into antiquity, with depictions appearing in Egyptian art and Greek literary sources. Ancient physicians operating within humoral frameworks attributed such conditions to imbalances in the fundamental bodily qualities, particularly coldness and moisture, which were believed to retard the vital processes necessary for proper bodily development. No concept of a glandular origin existed, and the pituitary gland itself, when noted at all by early anatomists, was long thought to be responsible for producing nasal mucus rather than regulating growth.
Galen in the second century described the pituitary as a structure that filtered waste from the brain and discharged it downward, a misapprehension that persisted with remarkable tenacity through the medieval Islamic medical tradition and into Renaissance European anatomy. Avicenna's Canon of Medicine, one of the dominant medical authorities of the medieval world, offered no specific account of growth disorders tied to the pituitary, though it addressed conditions of bodily underdevelopment in humoral terms. The anatomical revolution of the sixteenth century brought more careful dissection of the skull base and pituitary region, but functional understanding lagged far behind structural description.
The true turning point came in the nineteenth century, when clinicians began correlating pituitary tumors and lesions observed at autopsy with patterns of abnormal growth seen during life. Pierre Marie, the French neurologist, described acromegaly in 1886 and linked it to pituitary enlargement, an observation that opened the door to the idea that the pituitary gland was an active regulator of body size and proportion. This work implied that deficiency of whatever the pituitary produced might conversely result in failure of growth, a logical inference that clinical observers began to pursue systematically.
Harvey Cushing, the American neurosurgeon working in the early twentieth century, made fundamental contributions to pituitary science through his surgical and pathological studies, describing syndromes of both pituitary excess and insufficiency and cementing the gland's central role in human growth and metabolism. His monograph on the pituitary body, published in 1912, synthesized decades of scattered observation into a coherent account of pituitary disease.
The biochemical isolation of the growth hormone molecule itself occupied researchers across several decades of the mid-twentieth century, with Herbert Evans and his collaborators at the University of California making critical early strides in extracting growth-promoting substances from pituitary tissue in the 1920s. Full isolation and characterization of human growth hormone was achieved in the 1950s through the work of Choh Hao Li and Harold Papkoff, who demonstrated that the molecule was a protein distinct from other pituitary secretions. Clinical trials using pituitary-derived human growth hormone in children with documented deficiency began in the late 1950s under the oversight of organizations such as the National Pituitary Agency in the United States, marking the first systematic attempt to treat the condition with the identified missing substance. The later discovery that preparations derived from cadaveric pituitary tissue carried the risk of transmitting Creutzfeldt-Jakob disease prompted a dramatic shift in sourcing and production methods during the 1980s, fundamentally altering the history of the field.
Key Historical Figures
Historical narrative only — this page describes how Growth hormone deficiency was understood historically. It is not medical advice and does not describe current diagnosis or treatment. Sourced from verified medical history references (NIH, Encyclopaedia Britannica, and standard medical history texts). See our medical disclaimer.